Search clinical trials for: PIK3CA Mutant

Total 702 results

Cancer Institute and Hospital, Chinese Academy...

Recruiting

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Targeted Therapy | HR+/HER2- Advanced Breast Cancer

China
German Breast Group
Roche Pharma AG

Recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (GeparPiPPa)

HER2-positive Breast Cancer

Germany
Criterium, Inc.
Novartis; Seagen Inc.

Recruiting

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

HER2-positive Metastatic Breast Cancer

United States
Relay Therapeutics, Inc.

Recruiting

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Unresectable Solid Tumor | PIK3CA Mutation

United States, Spain, France, Italy
Saint Luke's Health System
Novartis Pharmaceuticals

Recruiting

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

Metastatic Breast Cancer | HER2-negative Breast Cancer

United States
Haihe Biopharma Co., Ltd.

Not yet recruiting

Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

Advanced Breast Cancer
Marina N Sharifi
Novartis; University of Wisconsin, Madison

Recruiting

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | PIK3CA Mutant Metastatic Breast Cancer

United States
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Breast Neoplasms

China
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120)

Breast Cancer

United States, Korea, Republic of, Canada, United Kingdom, Australia, Belgium, China, Denmark, France, Hungary, Portugal, Spain, Taiwan, Thailand, Italy, Argentina, Brazil, Poland, Singapore, Germany, Greece, Hong Kong, Ukraine, Russian... and more
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Breast Cancer Stage IV

United States
Genentech, Inc.

Active, not recruiting

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Breast Cancer | Solid Tumor

United States, France, Spain, United Kingdom, Canada
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve)

Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Taiwan, Canada, Germany, Argentina, Israel, Korea, Republic of, Denmark, France, India, Chile, Netherlands, Singapore, Japan, Mexico
Korean Cancer Study Group

Active, not recruiting

Alpelisib and Capecitabine in Patients With PIK3CA Mutant mCRC Patients (ALCAP)

Metastatic Colorectal Cancer | PIK3CA Gene Mutation

Korea, Republic of
David Bajor

Active, not recruiting

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Colorectal Cancer | Rectal Cancer | Solid Tumor | Colon Cancer

United States
Novartis Pharmaceuticals

Completed

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

Taiwan, Switzerland, Korea, Republic of, Germany, United States, Japan
The Netherlands Cancer Institute
AstraZeneca; Boehringer Ingelheim

Unknown

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer (M14AFS)

Gastrointestinal Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms

Netherlands
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
Zhejiang Cancer Hospital

Recruiting

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

HER2 Gene Mutation | Bile Duct Adenocarcinoma Non-Resectable

China
Huashan Hospital

Not yet recruiting

Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma

Glioma | Glioblastoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
Neonc Technologies, Inc.

Not yet recruiting

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

High Grade Glioma | Pineocytoma | Diffuse Midline Glioma, H3 K27M-Mutant | Spinal Cord Tumor | Pediatric Tumor of CNS | Pediatric Tumor of Brain | Pediatric Tumor of Brain Stem | Choroid Plexus Carcinoma, Childhood
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Erasca, Inc.

Recruiting

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Advanced or Metastatic NRAS-mutant Melanoma

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer

United States
Jonsson Comprehensive Cancer Center

Not yet recruiting

A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma

Diffuse Hemispheric Glioma, H3 G34-Mutant

United States
University of Southern California
National Cancer Institute (NCI)

Not yet recruiting

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8

United States
Henan Cancer Hospital

Recruiting

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Fudan University

Not yet recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Lung Cancer | Minimal Residual Disease | EGFR Gene Mutation
Suzhou Genhouse Bio Co., Ltd.
Shanghai East Hospital; Shandong Tumor Hospital

Recruiting

A Phase I/II Clinical Study to Evaluate The Safety, PK, PD of GH55 in Patients With MAPK Mutant Advanced Solid Tumors

Advanced Solid Tumors With MAPK Signal Pathway Mutant

China
OX2 Therapeutics

Recruiting

CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent High Grade Glioma

United States
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC (NEOVADE)

Non Small Cell Lung Cancer | EGFR Gene Mutation

China
M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Myeloproliferative Neoplasm | Myelodysplastic Neoplasm | Pathway Mutant Myelodysplastic Syndromes

United States
Shandong University

Not yet recruiting

Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma

Ameloblastoma
Yonsei University

Not yet recruiting

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases (ELPIS)

Non Small Cell Lung Cancer

Korea, Republic of
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

KRAS G12C Mutant Advanced Solid Tumors

China
Sun Yat-sen University

Not yet recruiting

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA). (AERESA)

Lung Cancer

China
Immuneering Corporation

Recruiting

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Pancreas Adenocarcinoma | Non-small Cell Lung Cancer | Advanced Solid Tumor (Phase 1) | Malignant Melanoma (Cutaneous)

United States
MapKure, LLC

Recruiting

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

Colorectal Cancer | Pancreatic Ductal Cancer | Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

United States
Therapex Co., Ltd

Not yet recruiting

A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Carcinoma, Non-Small-Cell Lung | EGFR Mutant Advanced Non-Small Cell Lung Cancer
InxMed (Shanghai) Co., Ltd.
InventisBio Co., Ltd

Recruiting

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Solid Tumor

China
Terns, Inc.

Not yet recruiting

CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase

United States
Rigel Pharmaceuticals
Nationwide Children's Hospital

Not yet recruiting

Study of Olutasidenib and Temozolomide in HGG

Astrocytoma | High Grade Glioma | Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | Spinal Tumor | Astrocytoma, Grade III | Astrocytoma, Grade IV | IDH1 Mutation | WHO Grade IV Glioma | Thalamus Tumor | IDH1 R132 | IDH1 R132C | IDH1 R132H and other conditions

United States, Australia, United Kingdom, Canada, Germany, Netherlands
Revolution Medicines, Inc.

Recruiting

Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC)

United States, Puerto Rico
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) (SUPRAMAX)

Glioblastoma | Brain Neoplasms | Astrocytoma, Grade III | High-grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Brain Neoplasm, Primary | Brain Neoplasm, Malignant | Astrocytoma, Malignant | Brain Neoplasms, Adult

United States, Germany, Belgium, Switzerland, Netherlands
Samsung Medical Center

Not yet recruiting

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Non-Small Cell Lung Cancer Metastatic

Korea, Republic of
Rigshospitalet, Denmark
Karolinska University Hospital; Aarhus University Hospital; Sahlgrenska University... and other collaborators

Not yet recruiting

RE-irradiation of Diffuse MIdline Glioma paTients (REMIT)

Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Diffuse Glioma | Pontine Tumors | Brain Tumor, Pediatric | Thalamic Tumor
Jonathan Riess
National Cancer Institute (NCI)

Not yet recruiting

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Tango Therapeutics, Inc.

Recruiting

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | Pancreas Cancer | BRCA1 Mutation | BRCA-Mutated Ovarian Carcinoma | BRCA-Associated Breast Carcinoma | HRD Positive Advanced Ovarian Cancer

United States
Neonc Technologies, Inc.

Recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Gastroesophageal Junction... and other conditions

United States
Revolution Medicines, Inc.

Recruiting

Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors

Advanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

United States

Search clinical trials for: PIK3CA Mutant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations